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1. INTRODUCTION & PURPOSE 
This document details the rules proposed and the presentation that will be followed, as closely as 
possible, when analysing and reporting the results from FITNET-NHS. 
The purpose of the plan is to:  
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical 
practice, and that interpretation of a priori and post hoc analyses respectively is 
appropriate. 
2. Explain in detail how the data will be handled and analysed to enable others to perform 
the actual analysis in the event of sickness or other absence. 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but 
fall outside the scope of this analysis plan (although such analyses would be expected to follow 
Good Statistical Practice). 
This analysis plan and any subsequent revisions will be published in an open access online 
repository and therefore date stamped and publicly available. Additional analyses suggested by 
reviewers or editors of journals will, if considered appropriate, be performed in accordance with 
the Analysis Plan, but if reported the source of such a post-hoc analysis will be declared. 
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2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
The following summary of the study design is solely to inform this statistical analysis plan. The 
study protocol (Baos et al 2018) and update (Anderson et al 2019), and findings of the internal 
pilot phase have all been published in open access journals. 
2.1 Trial objectives and aims 
The overall aim of this study is to investigate whether CBT specifically designed for 
CFS/ME and delivered over the internet (FITNET-NHS) is effective and cost-effective 
compared to Activity Management for children with CFS/ME who do not have access to a 
local specialist CFS/ME service.  
2.1.1 Primary objective 
Estimate the effectiveness of FITNET-NHS compared to Activity Management in the NHS 
for paediatric CFS/ME.  
2.1.2 Secondary objectives 
Estimate the effectiveness of FITNET-NHS compared to Activity Management for those 
with mild/moderate co-morbid mood disorders (anxiety/depression).  
Estimate the cost-effectiveness of FITNET-NHS compared to Activity Management.  
Estimate the cost-effectiveness of FITNET-NHS compared to Activity Management for 
those with mild/moderate co-morbid mood disorders (anxiety/depression).  
2.2 Trial design and configuration 
A two parallel group randomised controlled trial, with internal pilot. 
2.3 Setting 
2.3.1 Primary Care Regions with No Specialist CFS/ME Service  
In the first instance, children and young people (aged 11-17 years) will be assessed by 
their GP, referred for local paediatric assessment (NICE guidance) and have bloods tests to 
exclude other causes of fatigue (NICE 2007). If there is no local specialist paediatric 
CFS/ME service (about 90% of UK), GPs and paediatricians (or equivalent specialist 
doctors) will be able to refer those with CFS/ME to the Bath Specialist paediatric CFS/ME 
Service. The Bath Specialist CFS/ME Service already receives >150 referrals annually from 
across the UK but is only able to offer assessment or minimal Activity Management.  
2.3.2 Bath Specialist CFS/ME Service  
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Referrals will be accepted by the Bath Specialist CFS/ME Service if the child has been 
assessed by a paediatrician (or equivalent specialist doctor) and has had screening blood 
tests done, in accordance with NICE guidance (NICE, 2007). 
2.4 Eligibility criteria 
2.4.1 Inclusion criteria 
• Age between 11 and 17 years inclusive. 
• Diagnosis of CFS/ME (made according to NICE guidance) at clinical assessment (NICE, 
2007).  
• Children without access to a local specialist CFS/ME service. 
2.4.2 Exclusion criteria 
• Not disabled by fatigue. 
• Fatigue due to another cause. 
• Children or parents unable to complete video calls (e.g. Skype) or FITNET-NHS 
modules (e.g. unable to read FITNET-NHS material, or significant developmental 
problems, or limited internet access, unwilling/unable to set up a personal email 
address / videocall account). 
• Report pregnancy at assessment. 
2.5 Description of interventions 
2.5.1 Activity Management (Comparator) 
Activity Management via telecare will be delivered by specialist CFS/ME clinicians 
(including Occupational Therapists, Psychologists, medics, Physiotherapists) from the Bath 
Specialist CFS/ME Service. Participants (parent/carer attendance is optional) will have up 
to six video (e.g. Skype) appointments (one assessment and up to five follow up, this is an 
increased upper limit on the number of sessions, introduced 23/10/2017). Activity 
Management therapy over video call will be delivered using the same treatment principals 
as face to face Activity Management treatment.  
Specialist clinicians will have a check list of mandatory, flexible and prohibited items to 
discuss during the initial assessment and follow-up video call sessions with the participant 
and will use a check list to collect data on which aspects were discussed. This will capture 
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information on the delivery of Activity Management by specialist service clinicians by 
collecting information on how many assessments and follow up video (e.g. Skype) calls 
were made to participants, how many telephone calls to local clinicians were provided 
and which mandatory and flexible areas were used in the treatment sessions. 
2.5.2 FITNET-NHS (Intervention)  
FITNET (Fatigue In Teenagers on the interNET) is an internet-delivered CBT package 
created for paediatric CFS/ME in the Netherlands. The programme has psycho-educational 
and CBT sections for children and a parallel programme for their parents. Children and 
their parents have separate accounts and log-ins. The psycho-educational sections are 
available after receiving log-in codes. These include: information on CFS/ME; the causes of 
CFS/ME; the relationship between CFS/ME, anxiety, depression and other illnesses; how 
the diagnosis is confirmed; treatment for CFS/ME; how to explain CFS/ME to friends and 
what the future (without CFS) is likely to look like. The CBT section is activated by a clinical 
psychologist once the child/parent has completed the psycho-educational sections.  
Participants will work through 19 interactive modules: first they will complete the psycho-
educational modules, then work through CBT modules over 6 months. Parent modules 
explore and address parent’s beliefs and behaviours towards their child with CFS/ME 
focussing on their role as carers. The modules for participants introduce CBT, present 
CFS/ME as a multi-factorial model, discuss the role of the family and develop treatment 
goals. The CBT modules focus on cognitive behavioural strategies with instructions on 
exercises for identifying, challenging and changing cognitive processes. Modules 1, 2 and 4 
introduce CBT and explain the role of therapists, present CFS/ME as a multifactorial model 
with predisposing, precipitating and maintaining factors and discuss the role of the family. 
Modules 3 and 5 focus on treatment goals including the goal of full-time education. 
Modules 6 to 19 focus on cognitive behavioural strategies with instructions on exercises 
on identifying, challenging and changing cognitive processes that contribute to CFS/ME. 
Children will be asked to do homework (answer questions and complete diaries). Whilst 
children are able to complete the modules at their own pace, they will be encouraged to 
work on and complete modules before the next appointment.  
After parents complete the psycho-educational sections, they separately complete the 
remaining CBT modules. These explore and address parent’s beliefs and behaviours 
towards their child with CFS/ME. In children younger than 15 years, parents are supported 
to act as a coach. In those older than 15, parents are encouraged to step back and support 
their child taking responsibility for their treatment. Parents complete diaries and 
questionnaires and there is a review function of all completed modules.  
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The FITNET-NHS clinical psychologists will make appointments and provide e-
consultations. E-consultations are an email exchange between the therapist and the 
participants which functions only on the FITNET-NHS platform. In addition, participants 
and parents are required to complete homework (for example, sleep-wake, and thoughts 
and feelings diaries). These will be discussed in the e-consultations and used to support 
behaviour change. The therapist works with parents and children separately and 
responding together is discouraged. Therapist and participants/parents arrange a 
convenient date and time for e-consultations, usually every 2 weeks, unless the 
participant/parent and therapist feel the need for this to be different. Participants and 
parents will be asked to complete homework/tasks within specified time frames. 
Therapists will also respond to participants parents within the specified time frame. 
2.6 Randomisation procedures 
An automated web randomisation service operated by the Bristol Randomised Trials 
Collaboration (BRTC) will be used. Participants will be randomised in a 1:1 ratio to receive 
either FITNET-NHS or Activity Management. Allocation will use minimisation to facilitate 
balance by age (two categories, 11-14 and 15-17 years) and gender and retain a random 
component to prevent accurate prediction of allocation (i.e. preserve allocation 
concealment). Because of the nature of the intervention, it is not practical to blind either 
the participant, family or the clinical service to treatment allocation. 
2.7 Trial committees 
FITNET-NHS has an independent Trial Steering Committee (TSC) and independent Data 
and Safety Monitoring Committee (DSMC). Safety outcomes will be reviewed by the Data 
and Safety Monitoring Committee and reported to the Trial Steering Committee. 
2.8 Outcome measures 
2.8.1 Primary outcome 
Our primary outcome will be disability measured using the Physical Function Scale (SF-36-
PFS) measured 6 months after randomisation. Disability is an important outcome (Parslow 
et al 2015) for children with CFS/ME and we have shown it is sufficiently sensitive in this 
patient group. We want to allow children with CFS/ME the longest possible window to 
return outcome data and therefore the permissible measurement window will be 
between 5 and 9 months after randomisation. (Ware 1993, Ware & Sherbourne 1992). 
2.8.2 Secondary outcomes 
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All secondary outcomes are measured at 3, 6 and 12 months unless otherwise specified. 
Secondary outcomes include:  
1. Physical Function: SF36-PFS (Ware & Sherbourne 1992) measured at 3 and 12 months 
after randomisation.  
2. Fatigue: Chalder scale (Chalder et al 1993) and Checklist Individual Strength (CIS) fatigue 
severity subscale (Beurskens et al 2000). 
3. School attendance (self-report school or home tuition)  
4. Mood: Revised Children’s Anxiety and Depression Scale (RCADS)(Chorpita et al 2000, 
Chorpita et al 2005)  
5. Pain visual analogue scale (Hawker et al, 2011)  
6. Clinical Global Impression Scale (White et al 2011)  
7. Quality of Life (EQ-5D-Y) [47] (Ravens-Sieberer 2010, Wille 2010) 
8. Parental completed: Healthcare Resource Use questionnaire 
9. Parental completed: Work Productivity & Activity Impairment Questionnaire General 
Health (WPAI:GH) (Reilly et al 1993) 
All these measures are important and relevant domains (Parslow et al, 2015) that are used 
in UK services, CAMHS and/or tested in previous trials (Nijhof et al 2012, Crawley et al 
2018). The EQ-5D-Y, Healthcare Resource Use questionnaire, and WPAI:GH will be 
considered in the health economics analysis plan. 
The measurement of school attendance is challenging during COVID-19 lockdowns. We 
will present measures of school attendance assessed before and after March 2020 to 
consider whether this variable is meaningful during school closure.  
2.9 Sample size and justification 
The Minimum Clinically Important Difference (MCID) for the SF-36-PFS is 10 points 
(Brigden 2018) which is approximately 0.4 standard deviations (SD).  
2.9.1 Full Study  
314 children have been randomised. Assuming 15% attrition (withdrawal or non-provision 
of primary outcome data) (Nijhof et al 2012, Crawley et al 2018), data on 266 children will 
be available for the primary analysis. This gives 90% power at 5% significance to detect a 
0.4 SD difference on SF36-PFS for our primary outcome.  
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2.9.2 Secondary outcome:  
For the secondary outcome looking at effectiveness in those with a comorbid mood 
disorder, 40% of 266 children (data analysed) = 106 children will be available for analysis 
in the co-morbid subgroup. This will give 53% power at 5% significance to detect a 0.4SD 
difference on SF36-PFS between treatment groups within this co-morbid subgroup group. 
2.10 Interim analysis 
No interim analyses of the primary outcome measure by trial arm are planned. 
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3. GENERAL ANALYSIS CONSIDERATIONS 
3.1 Analysis populations 
Full analysis set (for the primary, secondary and safety analyses in the main results 
report): All randomised participants who complete the primary outcome measure, in the 
treatment group to which they were allocated (i.e. an intention to treat, ITT, analysis of 
observed data). 
3.2 Derived variables 
Questionnaire measures item responses will be recorded using REDCap electronic data 
capture tools hosted at the University of Bristol (Harris 2009) and scale scores will be 
calculated within Stata. Missing items in partially completed scales or subscales will be 
imputed using the methods described in the scale’s development literature where 
available (Ware 1993).  
3.3 Procedures for missing outcome data 
The primary analysis will be based upon the observed data only. If primary outcome data 
are missing, sensitivity analyses will explore how robust the observed primary analysis 
results are under different assumptions about the missing data mechanism. Baseline 
variables will be compared between those with complete and those with missing primary 
outcome data, according to allocated group, in supplementary material. 
3.4 Outliers 
Outlying scores on the questionnaire measures are unlikely to be extreme enough to be 
overly influential on treatment effect estimates. 
3.5 Software 
Data analyses will primarily be carried out using Stata statistical software (StataCorp, 
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4. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
4.1 Disposition 
A flow of patients through the trial will be summarised in a CONSORT diagram that will 
include the eligibility, reasons for exclusion, numbers randomised to the two treatment 
groups, losses to follow up and the numbers analysed. 
4.2 Baseline characteristics 
The following data will be collected from participants at baseline (see Table 1): age, sex, 
ethnicity, months of illness, diagnosis of co-morbid illnesses. 
Participants will complete the following questionnaires: SF-36 physical function subscale 
(SF-36-PFS), Fatigue (using Chalder Fatigue Scale and Checklist Individual Strength (CIS) 
fatigue severity subscale), school attendance (% possible school attendance), RCADS, Pain 
visual analogue scale, EQ-5D-Y (EuroQoL health related quality of life questionnaire, Youth 
version) and Clinical Global Impression Scale questionnaire.  
Continuous data will be summarised in terms of the mean, standard deviation, and 
number of observations.  Categorical data will be summarised in terms of frequency 
counts and percentages. 
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5. ASSESSMENT OF STUDY QUALITY 
5.1 Eligibility checks 
Eligibility assessments will be carried out by a specialist nurse during the initial clinical 
assessment assisted by standardised measures. 
5.2 Data validation 
Data are collected into REDCap data capture system (Harris 2009) with range checks for 
variables. All baseline and follow-up data are collected onto REDCap. Baseline data is 
collected on REDCap as soon as the participant is randomised. An automated email with 
the link to the follow-up questionnaires is sent to the participant via the REDCap at various 
follow-up time points.   
5.3 Intervention adherence 
We will record the number of participants who start their allocated intervention, and the 
number of modules/sessions completed (Table 2). Therapists will be asked to record the 
expected number of modules/sessions for each participant. 
5.4 Protocol deviations 
Protocol deviations which may affect the estimation of the treatment effect will be 
recorded and reported in the main study reports. For example, we will record instances of 
a participant being found to be ineligible after random allocation. 
5.5 Changes made to the planned statistical analyses 
The planned statistical analysis is described in this Statistical Analysis Plan, which has been 
written by co-investigators who have not had sight of the study data, and which will be 
signed and made public ahead of the analysis proceeding. Changes to the plan will be 
highlighted and justified in a revised version of the Statistical Analysis Plan. 
Changes to the pre-specified analysis, the need for which is recognised during the analysis, 
will be highlighted in study reports and publications, and fully justified. 
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6. ANALYSIS OF EFFECTIVENESS 
6.1 Primary analysis 
The null hypothesis to be tested is that the population mean SF-36-PFS score at six months 
follow-up is equal between groups allocated to FITNET-NHS or to Activity Management. This 
null hypothesis will be tested in an intention-to-treat analysis, which will compare study 
participants who completed the required measures, in the treatment groups to which they 
were allocated (the full analysis population). We will employ multivariable linear regression 
adjusting for baseline values of the outcome, baseline age and gender. The treatment effect 
will be estimated as an adjusted difference between sample means, which will be presented 
with 95% confidence interval and p-value (Table 3). 
The adjusted difference in means will be estimated in a linear regression model with 
patient response at six months post-randomisation (yi) as the outcome variable and 
covariates: treatment allocation (x1i=1: FITNET-NHS; x1i=0: activity management), baseline 
SF-36-PFS (x2i), age at recruitment (x3i as a continuous measure), and gender (x4i=1: male; 
x4i=0: female). Finally a dummy variable distinguishing those participants without a 
baseline assessment of outcome (x5i=1: no baseline assessment; x5i=0: baseline assessment 
available) (Groenwold 2012). A normal distribution is assumed for the residual errors: 
ei~N(0,σe). The coefficient for the treatment allocation covariate (β1) is the intention to 
treat estimate of treatment effectiveness, comparing FITNET-NHS to activity management. 
In statistical notation: 
𝑦𝑖 = 𝛽0 + 𝛽1𝑥1𝑖 + 𝛽2𝑥2𝑖 + 𝛽3𝑥3𝑖 + 𝛽4𝑡𝑥4𝑖 + 𝛽5𝑥5𝑖 + 𝑒𝑖 
 
The residuals from the model will be checked for a normal distribution, and as having a 
similar standard deviation in the two treatment groups. If the model assumptions are 
grossly violated, a sensitivity analysis will be conducted comparing the confidence interval 
to that from a bias corrected and accelerated percentile bootstrap method. 
6.2 Sensitivity analysis 
Sensitivity analyses to assist with the interpretation of the primary result will also be 
presented in Table 3. For the primary outcome we will conduct sensitivity analyses in 
which we further adjust our primary analysis model for prognostic variables (i.e. baseline 
variables presented in Table 1) for which there is a baseline imbalance between 
intervention arms (more than half a standard deviation between means, more than 0.1 
between proportions). This analysis will also adjust for any variation across participants in 
the time between randomisation and the six-month outcome assessment. 
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The primary analysis will be repeated with the addition of a binary covariate, 
distinguishing participants recruited before and after 1st September 2019, i.e. according to 
whether the six-month assessment is due before or during the COVID-19 pandemic. 
During the COVID pandemic, we are aware of delays following allocation before which 
treatment could commence. We will conduct a sensitivity analysis that reproduces the 
primary outcome analysis, but for any participants who did not commence their 
intervention until after the 3-month assessment point, and hence may not have 
completed the intervention by the 6-month primary assessment point, their data from the 
12-month assessment (if available) will be used instead. To help interpret this analysis, it 
will also be conducted with omission of those participants who did not commence their 
intervention until after the 3-month assessment point. 
We will estimate the effectiveness of FITNET-NHS compared with Activity Management 
for the SF-36-PFS primary outcome in participants completing one or more 
modules/sessions of their allocated intervention. This is a change from the corresponding 
sensitivity analysis described in the published protocol paper (Anderson 2019), which can 
more easily be applied in an equivalent manner to participants irrespective of their 
allocation.  Estimates from this analysis will be interpreted cautiously, with reference to 
the baseline measures of included participants, as this approach may allow biased 
estimates. 
6.3 Secondary analyses 
The primary analysis will be adapted to each of the other questionnaire measures at first 
and second follow-up assessments in turn (with the twelve-month assessment of SF-36-PF 
included as a secondary outcome). The corresponding baseline measure of the 
questionnaire being analysed will be included (Table 4). 
The primary analysis will also be adapted to the Clinical Global Impression Scale, with an 
ordered logistic regression model being employed. The seven response categories will be 
kept separate when included in this model (Table 5). There is no baseline assessment of this 
measure. 
6.4 Sub-group analysis 
In a single pre-defined subgroup analysis, we will estimate the effectiveness of FITNET-
NHS compared with Activity Management on the primary outcome in participant 
subgroups defined by the presence or absence of baseline anxiety or depression, defined 
by using the age and gender specific clinical thresholds for each sub-scale on the RCADS. 
Evidence that the intervention effect differs between subgroups will be examined by 
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adding interaction terms to the multivariable linear regression model for the SF-36-PFS 
primary outcome only. 
7. ANALYSIS OF SAFETY 
7.1 Deterioration in physical function  
The FITNET-NHS trial will investigate whether young people randomised to one arm are at 
higher risk of having a serious deterioration compared to another arm (Table 6). We will 
define a serious deterioration in health as:  
1. Clinician defined clinical change or illness reported to the clinician and forwarded on to 
the study team (clinical-reported serious deterioration in health) during treatment. This 
will be unexpected or unexplained deterioration in health as defined by the clinician or 
unexpected health outcomes that are not normally seen by CFS/ME specialist clinicians.  
2. A decrease of ≥20 in SF-36-PFS between baseline and 3, 6 or 12 months; or scores of 
“much” or “very much” worse on the Clinical Global Impression scale  
3. Withdrawal from treatment and participant or parent/carer says this is because they 
are feeling worse  
In supplementary material we will present these data separately for participants 
completing their twelve months follow-up prior to April 2020, and for participants whose 
follow-up was at least partly in the pandemic period. 
7.2 Safety Analyses  
The DSMC will specify how many independent safety reviews should be conducted and 
when these should be done. These reviews will only investigate safety outcomes and will 
be conducted by a statistician with un-blinded results provided to the DSMC. These data 
will be reviewed by the DSMC and reported to the TSC.   
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Reporting of the FITNET-NHS methodology and results will follow the CONSORT 





9. REVISIONS TO THE STATISTICAL ANALYSIS PLAN 
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10. PRIMARY REPORT TABLES AND FIGURES 




Management (n= ) 
Mean age (SD)   
Number female (%)    
Number white British ethnicity (%)   
Median months since illness onset (25th, 75th 
percentiles) 
  
Number comorbid anxiety1 (%)   
Number comorbid depression1 (%)   
Mean SF-36 Physical Function score (SD)   
Mean Chalder Fatigue score (SD)   
Mean CIS Fatigue score (SD)   
Mean pain VAS (SD)   
School attendance in the previous week2:   
Number recruited during school closure (%)   
  Number 0 days (%)   
  Number 0.5 days (%)   
  Number 1 day (%)   
  Number 2 days (%)   
  Number 3 days (%)   
  Number 4 days (%)   
  Number 5 days (%)   
1. Determined using the RCADS. 
2. Data has been collected on the number of hours of home tuition; this will be reported in the text 
accompanying this table.  
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Number not starting allocated treatment (%)   
Number completing 80% or more of expected 
modules / sessions of allocated treatment (%) 
  
Number starting allocated treatment more 
than three months after allocation (%) 
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Table 3. Summary statistics and treatment effect estimates for the Short Form 36 physical 
function at 6- (primary outcome measure) and 12-months 
 FITNET-NHS  Activity 
Management 
 




 Mean (SD), N Mean (SD), N 
Primary analysis  
(6 months) 
    
     
Sensitivity analyses:     
6 months: Further 
covariates1 
    
6 or 12 months 
according to start of 
allocated intervention 
    
 6 months: Participants 
attending 1+ sessions 
    
     
Subgroup analysis2:     
6 months: Participants 
with co-morbid mood 
disorder 
    
6 months: Participants 
with no co-morbid mood 
disorder 
    
     
Secondary analysis:     
12 months      
1. Covariates added for measures not balanced at baseline, and for exact time of primary outcome 
completion 
2. P-value is for interaction 
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Table 4. Summary statistics and treatment effect estimates for the secondary outcome 
questionnaire measures at 6 months and 12 months 




means (95% CI) 
 
p-value 
 Mean (SD), N Mean (SD), N 
Chalder Fatigue 6 months     
Chalder Fatigue 12 months     
CIS Fatigue 6 months     
CIS Fatigue 12 months     
Pain VAS 6 months     
Pain VAS 12 months     
School attendance 6 months1     
School attendance 12 
months1 
    
1. As a proportion of full time  
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Odds ratio (95% CI)  p-value 
Change from baseline (6 
months) 
    
Much better or very much 
better (%) 
    
Minimal change (%)1     
Much worse or very much 
worse (%) 
    
     
Change from baseline (12 
months) 
    
Much better or very much 
better (%) 
    
Minimal change (%)1     
Much worse or very much 
worse (%) 
    
1. Includes the responses “no change”, “a little better”, and “a little worse”. Categories are not combined 
when estimating the odds ratio 
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Number of participants with clinician report of 
worsening condition (%) 
  
Number of participants reporting worsening 
condition on withdrawing from treatment (%) 
  
Number of participants with evidence of 
worsening condition from SF-36 Physical 
Function or the Clinical Global Impression scale 
(%)1 
  
Number of participants with any evidence of 
worsening condition – one or more of the 
above (%) 
  
1. A decrease of ≥20 in SF-36-PFS between baseline and 3, 6 or 12 months; or scores of “much” or “very 
much” worse on the Clinical Global Impression scale 
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Figure 1. CONSORT recruitment and retention flow chart 
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APPENDIX: DETAILS OF STANDARD ASSESSMENT TOOLS 
Chalder Fatigue Scale (Chalder 1993): A self-completed 14-item measure of fatigue, with four 
response options per question: “better than usual” (score 0), “no more than usual” (score 1), 
“worse than usual” (score 2) and “much worse than usual” (score 3). Items include “Do you have 
problems with tiredness?” and “Do you have difficulty concentrating?”. The range of scores is 0 
to 42, with higher scores being most fatigue. 
The CIS fatigue scale (Beurskens et al 2000) was used to measure fatigue, it consists of 20 
statements for which the person has to indicate on a 7 point scale to what extent the particular 
statement applies to him or her. The statements refer to aspects of fatigue experienced during 
the previous 2 weeks. The number of items per dimension varies. The dimension “subjective 
fatigue” has eight items—for example, I feel tired—”reduction in motivation” four items—for 
example, I feel no desire to do anything—”reduction in activity three items—for example, I 
don’t do much during the day—and reduction in concentration five items—for example, My 
thoughts easily wander. Also, by adding the four dimensions a CIS total score can be calculated. 
Higher scores indicate a higher degree of fatigue, more concentration problems, reduced 
motivation, and less activity. 
Short Form 36 Physical Function (Ware 1993, Ware & Sherbourne, 1992):  A self-completed 10-
item sub-scale of the Short Form 36. Response options are “Yes, limited a lot”, “Yes, limited a 
little” and “No, not limited at all”. The range of scores is 0 to 100, with higher scores being the 
best function. 
Pain Visual Analogue Scale (Hawker 2011): The respondent places a line perpendicular to the 
100mm long VAS line at the point that represents their pain intensity. The score is determined 
by measuring the distance from the “no pain” anchor to the respondent’s mark. The range of 
scores is 0 to 100, with higher scores indicating greater pain intensity. 
Clinical Global Impression Scale (White 2011): Participant completed, assessing change from 
baseline with seven response categories. Here we follow White and colleagues in grouping the 
response categories into negative change (“Very much worse” or “Much worse”), minimal 
change (“A little worse”, “No change” or “A little better”), and positive change (“Much better” 
or “Very much better”). 
The Revised Children’s Anxiety and Depression Scale (RCADS, Chorpita et al 2000, 2005) consists 
of 47 items developed to measure DSM-IV relevant symptoms of anxiety disorders (GAD, SAD, 
SoP, Panic disorder, OCD) and Depression in children. It is scored on a 4-point scale (0 = never, 1
= sometimes, 2 = often and 3 = always). 
 
